9999999997-16-027773.txt : 20161215
9999999997-16-027773.hdr.sgml : 20161215
20161215170448
ACCESSION NUMBER: 9999999997-16-027773
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20161215
DATE AS OF CHANGE: 20161215
20161215
20161215
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cerulean Pharma Inc.
CENTRAL INDEX KEY: 0001401914
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 204139823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36395
FILM NUMBER: 162054324
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-996-4300
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Tempo Pharmaceuticals Inc
DATE OF NAME CHANGE: 20070604
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C0P(# @;V)J#3P\+TQI;F5AF4@-3,O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)D$&!@
M8F#R A(,4X $XWT@P1(*)-C=@,0G'@8F1H;M(%D&1G3B/^.')E9@T*, T*)25%3T8-"B @(" @
M(" @#0HU,B P(&]B:@T\/"]#(#8Y+T9I;'1E8F!@8&%@8(IF *>.0RH@)$!
M),O1@"S& L4,#/<9N!DX;QNW&$"5\G=!:*8&9,6*_!!11D& , ).0%N T*
M96YD7!E+T]B
M:E-T;3X^M#=!",1N30-M*+%I"B$/
MJBUL@2T%2:'-WW=GI%VM%=MI_5(*.5EIYZ(SL[/'TA!&I"7<$ID2H1AQ?UP*
M110G7+M_#_1F.IUD3;XB4CGGN\?+2WK=+/.R)9P)3:?9TZ>\6&]:HK6@'_+.
M=)$P0V?;;-V01-)95;:32?7KX4(IBS8B&&.8X!&MLVQ7;%_>+8I=WI#;_">Y
MJW99^1YMM]DNIVAQ!MS_.K^85-O5EP7:YVV=M\L-O:WJ7;;%K?N.D6&,WK39
MMEA>E^MM3AB=M_GN&^&)IHN7IQQ]@7)=/+553;_WE4AEKJY
M@9S+O&HWS8,QEOQ+P&@D24*40LAC
MV "WGR:,&"'2",%P5;"JOCDJXN%/(.Y<
MM^&RAA<(P9+4$!ZG\*D[YQ#5$P1BX"'[3HH1 0\@ZSD8Z;[F;6;8P^)@SRD-
MV!/?5..:( =FW7X7;]0 %1W2&.$$<20B8"$10M"!&0>R?D3&@/$))WD X --
M&@.F($:8A$-Y9+HW*0%#S"/*4I!?I[%_*;]Z7WZ9.4]^WU1>>41Y+3LMO-*>
M%-XS-==-SW^LN9(-\@F* C9N1U=9R[,E-\RFR^$!LYL*OG>GXGO@[P5RZ.\5
MV&QTQ[P?Q*+D"7^/#_VD.%YQ3\:*
M*UT_!3Q;N(?\H.*"WVG%A>I1<#E_);A>$5X);FK/T-N(@=%0N@YCX/=.Z:U4
MR;[>\M=Z*Z,C&@,*];^^,4+.'L?BL?WZ>'XO>XG^_>Z.%/5BV>XZ+( 9
MBB)Y=\\]]Z*W6>_Z WO]^OK]X&[(//;FS=OA@/6N!P\>F^UA@>UGF]YUEGE,
MLNRI)Q5S/5B&_[X7L=A+1!JQ+.]QYF1_]6[>X^'J0EE>Z#%7"AFR;'ABI[([
MA>?Y+)N!'#U[8:XOTK2\8-X;\T
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MR^W2%U+6=@]P-R$6E(@%J(TG8J7EC_GB^8#1L$;#%Q,T98//VM
M/--:#I;2XQ4.[ XQH",ST3(Z%9"LSI@I;>9S Y&DE\R4-J^YD0B#NL=O'2GY
M"H%?XX AQD; MJW0SN*>AS=RB6-8A9JKO>'[YMFG79&?AC0A-?0FOQ6?A*HL
M495H[ACP=E-^^T/;]Q6W_2"0JKKZR$*;C]U4J#H@?W3]G;G()E& S#",VA!+/B!!ECB=T(X<7TXT@\!C
M'H1@RFGK$8L2H1HLL@G M1E@S/<.24T@QRJ>KXK6'6->E+R8LPF,&QIW.Z(+
M$0=3-:X5=F6[88?-7*=KWT0]OT<5(,Y"OS3Y8"B'KZ50JJXK5\&TXI"J.%0C
MP1CC*B;=/A]PW"- E1J;/^GJ0*3R @RN[Z,K:G$Q@YRU!40V\'N"*KV:4V&*
M:*%836"V9L4SO,%%?"QR^UJG #R&5SQ3KEN5-^FED.=T:%4*8:N"X05?*2'@
M]0=8-5*%I!E[##O++:=?BZ6CH2S* +JO*_E+.&.%3I^52 /&);^
M B]FJ!R[=9+*@IRUA4FO%N5*)"7=?]-*Q.HB^0C9->I$YK4$H%?">@X'7FF_
M4X;Z@B[/T='3%M5\TQZ@=@)'Z/KBL_FT:A)HZZ5\&IT*]3%_"XE_4G)1APVJ
MC81 #7%E9VEK-VV(M>THPM?@E2F=_MN!8#<&GDHHD*ADU)U1Y'>E%)+2
MBZXMD%M$<4;3%1'L8A1\AN%@3JY7Q ^DAV8GJM%AM:M\$=0;N\F>U+(*>Q4W
M#8$P9VTW3^ 0@GI>^6"E':$31QR48%*J8G2,*)?KU 7 H5=Q'0Y*[4*]=TN$
MM"(VE#R[-NK7N)&.Y%U,:.13>K&D4DW^N74BPRVL&T@YK2/;/E%,X)X[F%V2
MH?$-1=C(A'U'IWC:>@7M]",LB >DAQA@^R=8&*I/'*Z=?G)@I&E TRLMO*8P
M]O,P"H:/LJKNJ##XGG,=X=IL[JMR6,Z .>5WK/2A5L;Q]J9=*-@3$,'\FD@:^9E90)8\*RY
M]HKAZ:^$EKWV,->*-@@"F:/;>_@>)1C?US"GDVO;XVU?G*I @KR:Z"4M3XT1
M" BD8%N8P;'-IF]OGLLF#7S>W'"ZW@9"-5CV@H&Q7C-, ENJH5-3<%E99-='
MKUJOJ<._J6
MZX@>BT_5GTਆ F: UE)[F%/5Q9^IL&T 9%P!4&\S"LIX_WO*OH+ Q -T
MYV%BBW C)X/=])4(O1#J6TL:E!_7-LL31295XB\_60Z:1UL;PX7)YP:-%Q:+
MJ.QH7FG057K68=(Z+/Z&?E&IH\@ZVN)?WG+Z _._/NBVM>Q/C0_>4?[\O6DX_=.0!:] #-KF+&47^HJ .US3AKI*5[TTD
M^").SIH25:9(W-OE\9NL]X\ P AV@%K#0IE;F1S=')E86T-96YD;V)J#30U
M(# @;V)J#3P\+T9I;'1E+V!-+B@J =('@-@H);4X&4A_
M >+,\I("H#AC I MDI0-9H/4B62'!#D#V1U -E]):@5(C,$YOZ"R*#,]HT3!
MT-+24L$Q)3\I52&XLK@D-;=8P3,O.;^H(+\HL20U!:@6:@<(\+L7)58JN"?F
MYB8J&.D9D>AR(@ H+"&LSR'@,&(4.X\00X#DTJ(R*).1R9B! 2# $G&."\-
M"F5N9'-T7!E+T]B:E-T;3X^G8@"(!<&Y'+A?
MV1)L#E51@2V@SC+@1IV<#NJ*+=S/D#TU:\E$-EB&H64M$# QZP*0MT#B[[P$
M*PM8,)V+M)1*!^AXF[2.>7E!/!EK70(QKZ T(VN%D(8K>3$QK^3]B'F.IR;F
MN2('8IZK'1#SJCR#BPMSRZ?-X,ZLV^#[N G>\\G_;:S\:[SU1[#F;CCX;^W(
MMY(-&/;F\L0NY_M-IJUN>H>#]VP"^VX/Z9BV<=P--?[-D1S
MT^VFX,WGKN7OS^7[:A&\_EZ,/?C0UG>S6\ING-??_DPYFT6/S?,M=:+:26IGKG86:F>I=CJULU([:_W-
MOR,D?4I6'Y/5YV3U05E]4E8?E=5G9?5A67U:J$\+W_&?TJ>%^K10GQ;JTT)5
M6K\%& !,,_K:#0IE;F1S=')E86T-96YD;V)J#3(@,"!O8FH-/#PO3&5N9W1H
M(#,V,C8O4W5B='EP92]834PO5'EP92]-971A9&%T83X^G)E4WI.5&-Z:V,Y
M9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM
M<'1K/2)!9&]B92!835 @0V]R92 U+C0M8S P-2 W."XQ-#&UL;G,Z>&UP34T](FAT=' Z+R]N&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O
M<'5R;"YO&UL;G,Z
M<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @
M("!X;6QN&UP.DUE=&%D871A1&%T93XR,#$V+3$R+3$U5#$W.C S
M.C4Q+3 U.C P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.D-R
M96%T;W)4;V]L/D%C&UP34TZ&UP34TZ#I3;W5R8V5-;V1I9FEE9#X*(" @(" @(" @
M/'!D9G@Z0V]M<&%N>3Y396-U&AA;F=E($-O;6UI3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(#PO7!E+T]B:E-T;3X^Y
MF\V@3:)5E%(0JY."X."<-KR,X.+D=.#_?? T2RC+?QM 39]&+
M?$?#PXRO[()M9!<<>C"CA?VS-^,-(=V#\][1F%)&$]*J3<"LWFBIEDJK0JWD
MO%!364RDG'RKA&];IL8$.->'D[DC@U+0$<.5V(K\1/8_8'-0R"+@8%QT!),#X$$(P- @ $ ]J@%5PT*
H96YD